The Latin America, Middle East and Africa Aspiration & Biopsy Needles Market would witness Market growth of 12.2% CAGR during the forecast period (2022-2028).
One of the primary factors expected to boost aspiration & biopsy needles Market growth and demand is the increased prevalence of breast and lung cancer. Moreover, it is due to the rapid rise in demand for less invasive procedures, as well as several governments and international health organization initiatives. Similarly, rapid technological advancements and development, as well as greater awareness of breast cancer early detection, are likely to propel Market growth.
Increased usage of minimally invasive operations for diagnosis, treatment, and prognosis, as well as an increase in the number of cancer cases. The rising frequency of chronic diseases such as diabetes mellitus in North America and Europe has increased the need for diagnostic technologies that might assist patients to be regularly monitored. During the projected period, this is expected to enhance the Market for aspiration and biopsy needles.
The issues in MENA nations are not only related to the rising rate of incidence, which shows a failure in primary prevention, but also in the diagnosis and management of affected individuals, particularly in light of recent improvements and the availability of more "expensive" management choices. In 2018, the number of new lung cancer cases was projected to reach 79,887. MENA has a 5-year relative survival rate of barely 8%, despite major breakthroughs in understanding and treating lung cancer. Morocco and Tunisia had the greatest percentages of deaths, while Yemen and Egypt had the lowest.
The bulk of lung cancer patients in the region are in advanced stages. In Yemen, for example, the median age of lung cancer diagnosis was 60 years, and over 75 percent of lung cancer patients in the country were in stages III and IV. As a result of the ineffective use of adequate therapy, the average post-chemotherapy survival period does not surpass 40 weeks.
The Brazil Market dominated the LAMEA Aspiration & Biopsy Needles Market by Country in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $29 million by 2028. The Argentina Market is experiencing a CAGR of 12.8% during (2022 - 2028). Additionally, The UAE Market would exhibit a CAGR of 11.9% during (2022 - 2028).
Based on Product Type, the Market is segmented into Biopsy Needles and Aspiration Needles. Based on Procedure, the Market is segmented into Image-guided and Nonimage-guided. Based on Image-guided Type, the Market is segmented into Ultrasound-guided, CT-guided, MRI-guided, Stereotactic, and Others. Based on End User, the Market is segmented into Hospitals & surgical centers, Diagnostic Clinics & pathology laboratories, Ambulatory care centers, Research & Academic Institutes. Based on Application, the Market is segmented into Tumor/ Cancer Applications, Wound Applications, and Others. Based on Tumor/ Cancer Applications Type, the Market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Bone & Bone Marrow Cancer, and Others. Based on countries, the Market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Aspiration & Biopsy Needles Market is Predict to reach $1.3 Billion by 2028, at a CAGR of 6.1%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Boston Scientific Corporation, Medtronic PLC, Johnson & Johnson, Merit Medical Systems, Inc., Cardinal Health, Inc., Becton, Dickinson and Company, ConMed Corporation, Olympus Corporation, Argon Medical Devices, Inc., and Cook Medical, Inc.
By Product Type
By Procedure
By End User
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 